Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in . 20,
Indo-Bangla Pharmaceuticals paidBDT0.00 Mil more to buy back shares than it received from issuing new shares.
It receivedBDT0.00 Mil from issuing more debt.
It paidBDT0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedBDT0.00 Mil from paying cash dividends to shareholders.
It receivedBDT0.00 Mil on other financial activities.
In all, Indo-Bangla PharmaceuticalsspentBDT0.00 Mil on financial activities for the
six
months ended in . 20.
Indo-Bangla Pharmaceuticals (DHA:IBP) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Indo-Bangla Pharmaceuticals's issuance of stock for the
six
months ended in . 20 was BDT0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Indo-Bangla Pharmaceuticals's repurchase of stock for the
six
months ended in . 20 was BDT0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Indo-Bangla Pharmaceuticals's net issuance of debt for the
six
months ended in . 20 was BDT0.00 Mil.
Indo-Bangla Pharmaceuticals receivedBDT0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Indo-Bangla Pharmaceuticals's net issuance of preferred for the
six
months ended in . 20 was BDT0.00 Mil.
Indo-Bangla Pharmaceuticals paidBDT0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Indo-Bangla Pharmaceuticals's cash flow for dividends for the
six
months ended in . 20 was BDT0.00 Mil.
Indo-Bangla Pharmaceuticals receivedBDT0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Indo-Bangla Pharmaceuticals's other financing for the
six
months ended in . 20 was BDT0.00 Mil.
Indo-Bangla Pharmaceuticals receivedBDT0.00 Mil on other financial activities.
Indo-Bangla Pharmaceuticals Cash Flow from Financing Related Terms
Indo-Bangla Pharmaceuticals Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals Cash Flow from Financing Chart
Indo-Bangla Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of BDT0.00 Mil mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Cash Flow from Financing of BDT0.00 Mil as of . 20. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Cash Flow from Financing too high?
Indo-Bangla Pharmaceuticals' current Cash Flow from Financing is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Cash Flow from Financing compare to ?
Indo-Bangla Pharmaceuticals' Cash Flow from Financing of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Cash Flow from Financing is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Cash Flow from Financing of BDT0.00 Mil. The current Cash Flow from Financing is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Cash Flow from Financing is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 
